Advances in Clinical and Experimental Medicine

Adv Clin Exp Med
Impact Factor (IF) – 1.227
Index Copernicus (ICV 2018) – 157.72
MNiSW – 40
Average rejection rate – 84.38%
ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download PDF

Advances in Clinical and Experimental Medicine

2019, vol. 28, nr 4, April, p. 515–522

doi: 10.17219/acem/87012

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Creative Commons BY-NC-ND 3.0 Open Access

Toll-like receptors TLR-2, TLR-4, TLR-7, and TLR-9 in tumor tissue and serum of the patients with esophageal squamous cell carcinoma and gastro-esophageal junction cancer

Dorota Diakowska1,A,B,C,D,E,F, Mirosław Nienartowicz2,B,E,F, Krzysztof Grabowski2,B,E,F, Joanna Rosińczuk1,C,E,F, Małgorzata Krzystek-Korpacka3,C,D,E,F

1 Department of Nervous System Diseases, Faculty of Health Science, Wroclaw Medical University, Poland

2 Department of Gastrointestinal and General Surgery, Wroclaw Medical University, Poland

3 Department of Medical Biochemistry, Wroclaw Medical University, Poland

Abstract

Background. Stimulation of toll-like receptors (TLRs) has been linked to the development of esophageal and gastric cancers.
Objectives. The aim of the study was to evaluate the clinical significance of tissue expression and serum concentration of TLR-2, TLR-4, TLR-7 and TLR-9 in patients with esophageal squamous cell carcinoma and gastro-esophageal junction adenocarcinoma.
Material and Methods. The study group consisted of 97 individuals: 32 with esophageal squamous cell carcinoma, 27 with gastro-esophageal junction cancer, and 38 ageand gender-matched controls. The mRNA expression and protein concentration of TLRs in tissues and sera were measured by reverse transcription polymerase chain reaction (RT-PCR) and enzyme-linked immunosorbent assay (ELISA) tests.
Results. In esophageal cancer patients, mRNA expressions of TLR-2, TLR-4 and TLR-7, and protein concentrations of all TLRs were significantly higher in tumor than in control tissue (p < 0.05). In esophageal cancer patients with lymph node metastasis, a tendency toward higher protein concentrations of tumor TLR-4 was observed. In gastro-esophageal junction adenocarcinoma subgroup, only the mRNA expression of TLR-7 and protein concentrations of TLR-4, TLR-7 and TLR-9 were significantly higher in tumors than in normal mucosa (p < 0.05). Protein concentration of TLR-9 was significantly higher in tumors of gastro-esophageal junction cancer with lymph node metastasis and depth of tumor invasion. Diagnostic potential of serum TLR-4 as a marker of gastro-esophageal junction cancer presence was reported.
Conclusion. We demonstrated differences in the expression patterns of TLRs between esophageal squamous cell carcinoma and adenocarcinoma of gastro-esophageal junction, and showed circulating TLR-4 to be a potential marker of gastro-esophageal junction cancer.

Key words

biomarkers, toll-like receptors, gastro-esophageal cancer

References (29)

  1. Napier KJ, Scheerer M, Misra S. Esophageal cancer: A review of epidemiology, pathogenesis, staging workup and treatment modalities. World J Gastrointest Oncol. 2014;6(5):112–120. doi: 10.4251/wjgo.v6.i5.112.
  2. Sehdev A, Catenacci DV. Gastroesophageal cancer: Focus on epidemiology, classification, and staging. Discov Med. 2013;16(87):103–111.
  3. Kauppila JH, Selander KS. Toll-like receptors in esophageal cancer. Front Immunol. 2014;5:200. doi: 10.3389/fimmu.2014.00200
  4. Sobin LH, Gospodarowicz MK, Wittekind C, eds. UICC: TNM Classification of Malignant Tumours. 7th ed. Oxford, UK; Chichester, UK; Hoboken, NJ: Wiley Blackwell; 2010; 63–77.
  5. Zaidi AH, Kelly LA, Kreft RE, et al. Associations of microbiota and toll-like receptor signaling pathway in esophageal adenocarcinoma. BMC Cancer. 2016;16:52. doi: 10.1186/s12885-016-2093-8
  6. Yang L, Francois F, Pei Z. Molecular pathways: Pathogenesis and clinical implications of microbiome alteration in esophagitis and Barrett esophagus. Clin Cancer Res. 2012;18(8):2138–2144.
  7. Lee CC, Avalos AM, Ploegh HL. Accessory molecules for toll-like receptors and their function. Nat Rev Immunol. 2012;12(3):168–179. doi: 10. 1038/nri3151
  8. Khan AA, Khan Z, Warnakulasuriya S. Cancer-associated toll-like receptor modulation and insinuation in infection susceptibility: Association or coincidence? Ann Oncol. 2016;27(6):984–997. doi: 10.1093/annonc/mdw053
  9. Ioannou S, Voulgarelis M. Toll-like receptors, tissue injury, and tumourigenesis. Mediators Inflamm. 2010;2010;9 pages. Article ID 581837. https://doi.org/10.1155/2010/581837. Accessed May 10, 2016.
  10. Paulos CM, Kaiser A, Wrzesinski C, et al. Toll-like receptors in tumor immunotherapy. Clin Cancer Res. 2007;13(18 Pt 1):5280–5289.
  11. Sheyhidin I, Nabi G, Hasim A, et al. Overexpression of TLR3, TLR4, TLR7 and TLR9 in esophageal squamous cell carcinoma. World J Gastroenterol. 2011;17(32):3745–3751. doi: 10.3748/wjg.v17.i32.3745
  12. Huhta H, Helminen O, Lehenkari PP, Saarnio J, Karttunen TJ, Kauppila JH. Toll-like receptors 1, 2, 4 and 6 in esophageal epithelium, Barrett’s esophagus, dysplasia and adenocarcinoma. Oncotarget. 2016;7:23658–23667. https://doi.org/10.18632/oncotarget.8151
  13. Fernandez-Garcia B, Eiró N, González-Reyes S, et al. Clinical significance of toll-like receptor 3, 4, and 9 in gastric cancer. J Immunother. 2014;37(2):77–83. doi: 10.1097/CJI.0000000000000016
  14. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402–408.
  15. Schmausser B, Andrulis M, Endrich S, Müller-Hermelink HK, Eck M. Toll-like receptors TLR4, TLR5 and TLR9 on gastric carcinoma cells: An implication for interaction with Helicobacter pylori. Int J Med Microbiol. 2005;295(3):179–185.
  16. Pimentel-Nunes P, Afonso L, Lopes P, et al. Increased expression of toll-like receptors (TLR) 2, 4 and 5 in gastric dysplasia. Pathol Oncol Res. 2011;17(3):677–683. doi: 10.1007/s12253-011-9368-9
  17. Mäkinen LK, Ahmed A, Hagström J, et al. Toll-like receptors 2, 4, and 9 in primary, metastasized, and recurrent oral tongue squamous cell carcinomas. J Oral Pathol Med. 2016;45(5):338–345. doi: 10.1111/jop.12373
  18. Avila M, Gonzalez-Espinosa C. Signaling through Toll-like receptor 4 and mast cell-dependent innate immunity responses. IUBMB Life. 2011;63(10):873–880. doi: 10.1002/iub.555
  19. Yuan X, Zhou Y, Wang W, et al. Activation of TLR4 signaling promotes gastric cancer progression by inducing mitochondrial ROS production. Cell Death Dis. 2013;4:e794. doi: 10.1038/cddis.2013.334
  20. Helminen O, Huhta H, Lehenkari PP, Saarnio J, Karttunen TJ, Kauppila JH. Nucleic acid-sensing toll-like receptors 3, 7 and 8 in esophageal epithelium, Barrett’s esophagus, dysplasia and adenocarcinoma. Oncoimmunology. 2016;5(5):e1127495. doi: 10.1080/2162402X.2015.1127495
  21. Lin KJ, Lin TM, Wang CH, Liu HC, Lin YL, Eng HL. Down-regulation of toll-like receptor 7 expression in hepatitis-virus-related human hepatocellular carcinoma. Hum Pathol. 2013;44(4):534–541. doi: 10. 1016/j.humpath.2012.06.015
  22. Ni YH, Ding L, Zhang DY, Hou YY, Huang X, Hu Q. Distinct expression patterns of toll-like receptor 7 in tumour cells and fibroblast-like cells in oral squamous cell carcinoma. Histopathology. 2015;67(5):730–739. doi: 10.1111/his.12703
  23. Vaz J, Andersson R. Intervention on toll-like receptors in pancreatic cancer. World J Gastroenterol. 2014;20(19):5808–5817. doi: 10.3748/wjg.v20.i19.5808
  24. Kauppila JH, Takala H, Selander KS, Lehenkari PP, Saarnio J, Karttunen TJ. Increased toll-like receptor 9 expression indicates adverse prognosis in oesophageal adenocarcinoma. Histopathology. 2011; 59(4):643–649. doi: 10.1111/j.1365-2559.2011.03991
  25. Takala H, Kauppila JH, Soini Y, et al. Toll-like receptor 9 is a novel biomarker for esophageal squamous cell dysplasia and squamous cell carcinoma progression. J Innate Immun. 2011;3(6):631–638. doi: 10. 1159/000329115
  26. Ghosh A, Dasgupta A, Bandyopadhyay A, et al. A study of the expression and localization of toll-like receptors 2 and 9 in different grades of cervical intraepithelial neoplasia and squamous cell carcinoma. Exp Mol Pathol. 2015;99(3):720–724. doi: 10.1016/j.yexmp.2015.11.015
  27. Mäkinen LK, Atula T, Häyry V, et al. Predictive role of toll-like receptors 2, 4, and 9 in oral tongue squamous cell carcinoma. Oral Oncol. 2015;51(1):96–102. doi: 10.1016/j.oraloncology.2014.08.017
  28. Pandey S, Singh S, Anang V, Bhatt AN, Natarajan K, Dwarakanath BS. Pattern recognition receptors in cancer progression and metastasis. Cancer Growth Metastasis. 2015;8:25–34. doi: 10.4137/CGM.S24314
  29. Aggarwal R, Misra S, Guleria C, et al. Characterization of toll-like receptor transcriptome in squamous cell carcinoma of cervix: A case-control study. Gynecol Oncol. 2015;138(2):358–362. doi: 10.1016/j.ygyno.2015.05.029